Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL. Stockley TL, et al. Among authors: chen ex. Genome Med. 2016 Oct 25;8(1):109. doi: 10.1186/s13073-016-0364-2. Genome Med. 2016. PMID: 27782854 Free PMC article. Clinical Trial.
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.
Bahl M, Siu LL, Pond GR, Kim J, Tannock IF, Bayley A, Cummings BJ, Waldron J, Ringash J, Chen EX, Gitterman L, Lemon B, O'Sullivan B. Bahl M, et al. Among authors: chen ex. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1127-36. doi: 10.1016/j.ijrobp.2004.05.011. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519784
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
Chen EX, Batist G, Siu LL, Bangash N, Maclean M, McIntosh L, Miller WH Jr, Oza AM, Lathia C, Petrenciuc O, Seymour L. Chen EX, et al. Invest New Drugs. 2005 Oct;23(5):455-65. doi: 10.1007/s10637-005-2905-1. Invest New Drugs. 2005. PMID: 16133797 Clinical Trial.
216 results